JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines

Mutations or deletions in exons 18–21 in the epidermal growth factor receptor (EGFR) are present in approximately 15% of tumors in patients with non-small cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this do...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Kani, Kian, Garri, Carolina, Tiemann, Katrin, Malihi, Paymaneh D., Punj, Vasu, Nguyen, Anthony L., Lee, Janet, Hughes, Lindsey D., Alvarez, Ruth M., Wood, Damien M., Joo, Ah Young, Katz, Jonathan E., Agus, David B., Mallick, Parag
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5558834/
https://ncbi.nlm.nih.gov/pubmed/28566434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0564
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller